24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

NCT02347085 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: GFF MDI (PT003)
DRUG: Placebo MDI

Sponsor

Pearl Therapeutics, Inc.